Skip to content

Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)

Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029625
Enrollment
Unknown
Registered
2020-02-07
Start date
2020-02-17
Completion date
Unknown
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Gold Standard:Clinical outcome
and&#32
prediction&#32
system

Sponsors

The First Affiliated Hospital of Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients with novel coronavirus infection pneumonia were confirmed by RT-PCR and clinical symptoms. The diagnosic criteria refer to "Pneumonitis Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 5)"; 2. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 10 days); 3. Patients who voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: Physician judged the patient was not suitable for this clinical trial (for example, patient may be transferred to another hospital during the study period; patient with immune system diseases or cancers etc.)

Design outcomes

Primary

MeasureTime frame
Lymphocyte subpopulation analysis;Cytokine detection;Single cell sequencing of bronchial lavage fluid cells;

Countries

China

Contacts

Public ContactCai Hongliu

The First Affiliated Hospital of Zhejiang University School of Medicine

caiicu@163.com+86 13505811696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026